Result: Risk Minimisation Materials for medicines starting with the letter T

Tasmar

Meda Pharmaceuticals

Tasmar Patient Diary

To help you keep track of your appointments for liver function tests during the first year

Tecentriq

Roche Products Limited

Tecentriq (atezolizumab) Patient Alert Card

This material is provided by Roche Products Ltd as a licence requirement for this medicine and forms part of the Risk Management Plan

For Healthcare Professionals

Tenofovir

Cipla EU Ltd

Educational Material: TENOFOVIR DISOPROXIL FOR ADOLESCENT CHILDREN WITH CHRONIC HEPATITIS B

RENAL RISK MINIMISATION MATERIAL: TENOFOVIR DISOPROXIL FOR ADOLESCENT CHILDREN WITH CHRONIC HEPATITIS B

For Healthcare Professionals

Educational material: TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1

RENAL AND BONE EFFECTS RISK MINIMISATION MATERIAL: TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1

For Healthcare Professionals

Accord Healthcare Limited

HBV Indications - children and adolescents v4

This material provides important information and advice on the management of potential renal and bone effects of the use of tenofovir disoproxil in adolescents with chronic hepatitis B aged 12 to <18 years.

HIV Indications - children and adolescents

This material provides important information and advice on the management of potential renal and bone effects of the use of tenofovir disoproxil in adolescents infected with HIV-1 aged 2 to <18 years.

Glenmark Pharmaceuticals Europe Ltd

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescent with HIV-1

HIV-1 Renal & bone effects education brochure - children and adolescent

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Chronic Hepatitis B education brochure – adolescent children

For Healthcare Professionals

Lupin Healthcare (UK) Ltd

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV1

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV1

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

Aurobindo Pharma - Milpharm Ltd.

Renal and Bone Effects Risk Minimisation Material Tenofovir Disoproxil for Children and Adolescents with HIV-1

This brochure contains important advice on the management of potential renal and bone effects of tenofovir disoproxil in HIV-1 infected children and adolescents aged 2 to <18 years, and the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

This brochure provides important advice on the management of potential renal and bone effects of Tenofovir disoproxil in adolescent patients with chronic hepatitis B aged 12 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with Chronic Hepatitis B

In adult patients with renal impairment, tenofovir disoproxil should only be used if the potential benefits of treatment outweigh the potential risks. A close monitoring of renal function is recommended.

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adults with HIV

HIV-positive patients are at increased risk of renal impairment, requiring baseline and subsequent renal monitoring. For those adult patients on tenofovir disoproxil based regimens specific recommendations are detailed in the risk minimisation material

For Healthcare Professionals

Dr. Reddy's Laboratories (UK) Ltd

Renal and Bone Effects Risk Minimisation Material: Tenofovir Disoproxil for Children and Adolescents with HIV-1

HIV-1 Renal & bone effects education brochure - children

For Healthcare Professionals

Renal Risk Minimisation Material Tenofovir Disoproxil for Adolescent Children with Chronic Hepatitis B

HBV renal education brochure - children

For Healthcare Professionals

Sandoz Limited

Renal and bone effects risk minimisation material: Tenofovir disoproxil for children and adolescents with HIV-1

This brochure provides important advice on the management of potential renal and bone effects of tenofovir disoproxil in HIV-1 infected children and adolescents aged 2 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals

Renal Risk Minimisation Material: Tenofovir Disoproxil for adolescent children with chronic hepatitis B

This brochure provides important advice on the management of potential renal and bone effects of tenofovir disoproxil in adolescent patients with chronic hepatitis B aged 12 to <18 years, and on the dosing recommendations for tenofovir disoproxil in this population.

For Healthcare Professionals

Zentiva

RENAL AND BONE EFFECTS RISK MINIMISATION MATERIAL:TENOFOVIR DISOPROXIL FOR CHILDREN AND ADOLESCENTS WITH HIV-1

Submission of Risk Minimisation Materials (coordinated by BGMA) to agency – minimising the risks of renal and bone effects for children and adolescents with HIV

Tenofovir disoproxil - Renal Risk Minimisation for adolescent children with chronic hepatitis B

For hard copies please contact our medical information department on 0800 090 2408 or email [email protected]

Aristo Pharma Limited

Tenofovir disoproxil for adolescent children with chronic hepatitis B

Renal risk minimisation material: Tenofovir disoproxil for adolescent children with chronic hepatitis B

For Healthcare Professionals

Tenofovir disoproxil for children and adolescents with HIV-1

Renal and bone effects risk minimisation material: Tenofovir disoproxil for children and adolescents with HIV-1

For Healthcare Professionals

Mylan

Tenofovir HBV Paediactrics Brochure

Tenofovir HBV Paediactrics Brochure advice for HCPs

For Healthcare Professionals

Tenofovir HIV Paediactrics Brochure

Tenofovir HIV Paediactrics Brochure advice for HCPs

For Healthcare Professionals

Thalidomide

Celgene Ltd

Thalidomide Adverse Event Form

The safe use of thalidomide is of paramount importance. Adverse events (and cases of suspected or confirmed pregnancy or foetal exposure) should be reported to Celgene. Any adverse event should also be reported to the MHRA via the Yellow Card scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

For Healthcare Professionals

Thalidomide Information for Healthcare Professionals

This brochure contains the information needed for prescribing and dispensing of thalidomide, including information about the Pregnancy Prevention Programme (PPP). It is a requirement of the PPP that all healthcare professionals ensure that they have read and understood the risk minimisation materials before prescribing or dispensing thalidomide for ANY patient. Please also refer to the Summary of Product Characteristics (SmPC) for thalidomide.

For Healthcare Professionals

Thalidomide Information for Patients

This brochure should be given to patients receiving treatment with thalidomide, as it provides important details about the Pregnancy Prevention Programme, including what a patient needs to be aware of before, during and after taking thalidomide and how to report side effects.

Thalidomide Male Treatment Initiation Form

This Treatment Initiation Form must be completed for each male patient, prior to the initiation of their thalidomide treatment. It is mandatory that males receive counselling and education to be made aware of the risks of thalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of thalidomide.

For Healthcare Professionals

Thalidomide Patient Pocket Information Card

This card must be provided to all patients to reinforce the safety information about thalidomide. It contains information on the risks of thalidomide if used during pregnancy, how to minimise these risks through the Pregnancy Prevention Programme, and what to do if a female patient or female partner of a male patient suspects they are pregnant, while on treatment with thalidomide.

Thalidomide Pharmacy Registration Form

This Pharmacy Registration Form must be completed by the Chief Pharmacist or appointed deputy to be able to order and dispense thalidomide. Dispensing of thalidomide will only be allowed from pharmacies registered with Celgene.

For Healthcare Professionals

Thalidomide Pregnancy Report and Pregnancy Outcome Forms

The safe use of thalidomide is of paramount importance. Any cases of suspected or confirmed pregnancy should be IMMEDIATELY reported to Celgene. Any suspected or confirmed pregnancy should also be reported to the MHRA via the Yellow Card scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

For Healthcare Professionals

Thalidomide Prescription Authorisation Form

A newly completed Prescription Authorisation Form must accompany each thalidomide prescription to confirm the patient has been counselled about the teratogenic risk of thalidomide and the required contraceptive methods, continues to use effective contraception, and in the case of a woman of child bearing potential, is having a pregnancy test every 4-weeks, before each prescription to ensure they are not pregnant. Completion of this information is mandatory for ALL patients.

For Healthcare Professionals

Thalidomide Treatment Checklist and Algorithm

This checklist is to assist you with counselling a patient before they commence thalidomide treatment to ensure it is used safely and correctly. The Algorithm provides high level steps for Pharmacy registration and dispensing of thalidomide.

For Healthcare Professionals

Thalidomide Woman of Childbearing Potential Treatment Initiation Form

This Treatment Initiation Form must be completed for each woman of childbearing potential, prior to the initiation of their thalidomide treatment. It is mandatory that women of childbearing potential receive counselling and education to be made aware of the risks of thalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of thalidomide.

For Healthcare Professionals

Thalidomide Woman of Non-Childbearing Potential Treatment Initiation Form

This Treatment Initiation Form must be completed for each woman of non-childbearing potential, prior to the initiation of their thalidomide treatment. It is mandatory that women of non-childbearing potential receive counselling and education to be made aware of the risks of thalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with the use of thalidomide.

For Healthcare Professionals

Accord-UK Ltd

Thalidomide Adverse Event Form

The safe use of this product is essential. Adverse events or any cases of suspected/confirmed pregnancy or foetal exposure should always be reported to Accord. Any adverse events can also be reported direct to the MHRA via the Yellow card scheme website: www.mhra.gov.uk/yellowcard or search for the MHRA Yellow Card in the Google Play or Apple App Store.

For Healthcare Professionals

Thalidomide Information for Healthcare Professionals

This material contains the information need by the healthcare professionals for prescribing and dispensing Thalidomide, including information about the Pregnancy Prevention Programme (PPP). It is a requirement that the healthcare professional ensures they read and understand the PPP prior to prescribing and dispensing thalidomide to ANY patient. Please also refer to the Summary of Product Characteristics (SmPC) for thalidomide.

For Healthcare Professionals

Thalidomide Information for the Patients

This material should be given to each patient receiving treatment with thalidomide as it provides important details about the Pregnancy Prevention Programme, including what the patient needs to be aware of before, during and after taking thalidomide along with how to report any side effects.

Thalidomide Male Treatment Initiation Form

This Treatment Initiation Form must be completed for each male patient prior to the initiation of their Thalidomide treatment. It is mandatory that all males receive counselling and education to be made aware of the risks of thalidomide. The aim is to protect the patient and any possible foetuses by ensuring the patient is fully informed of and understands the risk of teratogenicity and other adverse effects associated with the use of thalidomide.

For Healthcare Professionals

Thalidomide Patient Information Card

The patient card must be given to patients receiving treatment with thalidomide, as it provides important details about the Pregnancy Prevention Programme, including what they need to be aware of before, during and after taking thalidomide and how to report side effects.

Thalidomide Pharmacy Registration Form

The Pharmacy registration for must be completed by the chief Pharmacist or their appointed deputy to be able to order and dispense thalidomide. Pharmacies will only be able to dispense thalidomide if they are registered with Accord.

For Healthcare Professionals

Thalidomide Pregnancy Form

The safe use of this product is essential. Any cases of suspected pregnancy or confirmed pregnancy should be IMMEDIATELY reported to Accord. Any adverse events can also be reported direct to the MHRA via the Yellow card scheme website: www.mhra.gov.uk/yellowcard or search for the MHRA Yellow Card in the Google Play or Apple App Store.

For Healthcare Professionals

Thalidomide Pregnancy Outcome Form

The safe use of this product is essential. Any cases of suspected pregnancy or confirmed pregnancy should be IMMEDIATELY reported to Accord. Any adverse events can also be reported direct to the MHRA via the Yellow card scheme website: www.mhra.gov.uk/yellowcard or search for the MHRA Yellow Card in the Google Play or Apple App Store.

For Healthcare Professionals

Thalidomide Prescription Authorisation form

Each prescription of Thalidomide must be accompanied by a newly completed Prescription Authorisation Form to confirm the patient has been counselled about the teratogenic risk of thalidomide and the requirement for the use of contraception and the continuous use of an effective contraception whilst taking thalidomide. Also, for woman of childbearing potential the confirmation of having a pregnancy test every 4-weeks, before each prescription to ensure they are not pregnancy. Completion of this information is mandatory for ALL patients.

For Healthcare Professionals

Thalidomide Treatment Checklist and Algorithm

The thalidomide checklist is to assist the healthcare profession with counselling a patient before the commence thalidomide treatment to ensure it is used safety and correctly. The Algorithm provides high level steps for the process of Pharmacy registration and dispensing of thalidomide.

For Healthcare Professionals

Thalidomide Women of Childbearing Potential Treatment Initiation Form

This Treatment Initiation Form must be completed for each woman of childbearing potential prior to the initiation of their thalidomide treatment. It is mandatory that women of childbearing potential receive counselling and education to be made aware of the risks of thalidomide. Thalidomide is contraindicated in women of childbearing potential unless all terms of counselling are met. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with thalidomide.

For Healthcare Professionals

Thalidomide Women of Non-Childbearing Potential Treatment Initiation Form

This Treatment Initiation Form must be completed for each woman of non-childbearing potential prior to the initiation of their Thalidomide treatment. It is mandatory that women of non-childbearing potential receive counselling and education to be made aware of the risks of thalidomide. The aim of the Treatment Initiation Form is to protect patients and any possible foetuses by ensuring that patients are fully informed of and understand the risk of teratogenicity and other adverse effects associated with thalidomide.

For Healthcare Professionals

Toctino

Stiefel

Alitretinoin Patient Card

To be given by the dermatologist, specialist dermatology nurses, or prescribing GP to reinforce the key safety messages around risks.

Alitretinoin Pharmacist Checklist

To be used as an aide memoire by pharmacists when dispensing oral retinoid medicines.

For Healthcare Professionals

Alitretinoin Prescriber Checklist

To be used by the dermatologist, specialist dermatology nurse, or a prescribing GP with a special interest in dermatology to record the discussion of risks with the patient.

For Healthcare Professionals

Tolvaptan

Teva UK Limited

Tolvaptan Teva HCP Educational Guide

Tolvaptan Teva is a specialist product and additional training is required prior to prescribing. Please visit https://www.tevauk.com/healthcare-professionals/tolvaptan-hcp/ to register and complete the training. Training must be completed prior to prescribing Tolvaptan Teva. This guide has been developed for prescribers and healthcare professionals (HCPs) involved in the treatment of patients using Tolvaptan Teva. This document summarises important information on the potential risk of hepatic toxicity and provides guidance on how to manage this risk. In addition, it provides important information about pregnancy prevention before and during the treatment with Tolvaptan Teva.

For Healthcare Professionals

Tolvaptan Teva Patient Alert Card

Tolvaptan Teva is a specialist product and additional training is required prior to prescribing. Please visit https://www.tevauk.com/healthcare-professionals/tolvaptan-hcp/ to register and complete the training. Training must be completed prior to prescribing Tolvaptan Teva. This patient alert card should be used by patients who have been prescribed medicines containing tolvaptan, and should carry with them at all times when taking this medicine. This card contains important safety information that patient needs to be aware of before, during, and after treatment with Tolvaptan Teva.

Tolvaptan Teva Patient/Carer Education Brochure

Tolvaptan Teva is a specialist product and additional training is required prior to prescribing. Please visit https://www.tevauk.com/healthcare-professionals/tolvaptan-hcp/ to register and complete the training. Training must be completed prior to prescribing Tolvaptan Teva. The guide should be provided to patients by the prescribing physician and includes a description of the risks of treatment, guidance on what to do in the event of risks occurring and an overview of treatment monitoring.

Toujeo

SANOFI

Toujeo 300 units/ml, solution for injection in a pre-filled pen - Guide for Healthcare Professionals

This document is submitted as a guide to avoid medication errors and includes information which must be written on each prescription for Toujeo and key safety elements when switching from or to an insulin with a different strength. For hard copies please contact our medical information department at 0800 035 25251 or email [email protected]

For Healthcare Professionals

Toujeo 300 units/ml, solution for injection in a pre-filled pen - Guide for patients and/or carers

This document includes information such as what Toujeo is and how to use it. It is to be used as a guide alongside the full Instructions For Use leaflet which accompanies the pen. For hard copies please contact our medical information department at 0800 035 2525 or email [email protected]

Treprostinil

Dr. Reddy's Laboratories (UK) Ltd

Healthcare Professional Guide

Guidelines on the safe administration of Treprostinil Solution For Infusion by continuous intravenous infusion via an external infusion pump and central venous catheter (CVC) to prevent catheter‐related blood stream infections (CR‐BSI)

For Healthcare Professionals

Treprostinil Solution For Infusion Patient Questionnaire

A questionnaire for patients treated with intravenous Treprostinil via an external infusion pump and central venous catheter

For Healthcare Professionals

Treprostinil Solution For Infusion Patient Brochure

Administration of Treprostinil as intravenous infusion via an external pump and central venous catheter (CVC) (directly into a large vein)

For Healthcare Professionals

Tillomed Laboratories Ltd

Treprostinil Tillomed Solution for Infusion - Healthcare Professional Guide

The guide details the risk of central venous catheter related blood stream infections and sepsis associated with the intravenous route of administration of Treprostinil Tillomed Solution For Infusion

For Healthcare Professionals

Treprostinil Tillomed Solution for Infusion - Patient Brochure

This guide details the risk of central venous catheter related blood stream infections and sepsis associated with the intravenous route of administration of Treprostinil Tillomed Solution For Infusion

Treprostinil Tillomed Solution for Infusion - Patient Questionnaire

A questionnaire for patients treated with intravenous Treprostinil via an external infusion pump and central venous catheter (CVC)

Tresiba

Novo Nordisk Limited

Tresiba® 100U and 200U FlexTouch® correct use of Tresiba® (insulin degludec)-to-minimise-medication-errors

Direct Healthcare Professional Communication for Tresiba® 100U and 200U FlexTouch® correct use of Tresiba® (insulin degludec) to minimise medication errors

For Healthcare Professionals

Triumeq

ViiV Healthcare UK Ltd

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

For Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

For Healthcare Professionals

Trizivir

ViiV Healthcare UK Ltd

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

Abacavir Hypersensitivity Slide Deck for Healthcare Professionals

For Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

Abacavir Hypersensitivity Website for Healthcare Professionals

For Healthcare Professionals

Truvada

Gilead Sciences Ltd

Tenofovir Disoproxil Fumarate (TDF)) HIV Paediatric Educational Brochure

Brochure providing important advice on the management of potential renal and bone effects of TDF in children and adolescent patients with HIV-1 aged 2 to <18 years, and on the dosing recommendations for TDF in this population.

For Healthcare Professionals

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Checklist For Prescribers

Checklist For Prescribers from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Patient Leaflet

Patient Leaflet from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection. It contains Important Information About Truvada® (emtricitabine/tenofovir disoproxil fumarate) to Reduce the Risk of Getting Human Immunodeficiency Virus (HIV) Infection for individuals who have been prescribed Truvada® for Pre-Exposure Prophylaxis (PrEP)

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Prescribers Leaflet

Important Safety Information for Prescribers About Truvada® (emtricitabine/tenofovir disoproxil fumarate) for a Pre-exposure Prophylaxis (PrEP) Indication

For Healthcare Professionals

Truvada 200 mg/245 mg film-coated tablets (emtricitabine/tenofovir disoproxil fumarate) - PrEP Educational Materials - Reminder Card

Reminder Card for patients from the Physician educational pack for Truvada® (emtricitabine 200mg/ tenofovir disoproxil fumarate 245mg) for pre-exposure prophylaxis (PrEP) in patients at risk of sexually acquired HIV-1 infection.

Truxima

Napp Pharmaceuticals Limited

Truxima Administration Route

Clarification on the correct route of administration for Truxima. This product is for intravenous administration via infusion only.

For Healthcare Professionals

Truxima Patient Alert Card

Patient Alert Card

Truxima Patient Information

Information for Patients

Truxima Safety Sheet

Information for Healthcare Professionals

For Healthcare Professionals

Tysabri

Biogen Idec Ltd

Patient Alert Card

This alert card contains important safety information that you need to be aware of before, during and after stopping treatment with Tysabri (natalizumab). Hard copies can be requested by contacting Biogen at [email protected] or by telephone on 0800 008 7401.

Physician Information and Management Guidelines for Patients with Multiple Sclerosis receiving TYSABRI Therapy

This guidance document has been developed for those physicians initiating and supervising TYSABRI in accordance with the conditions of the Marketing Authorisation of the drug.

For Healthcare Professionals

Treatment Continuation Form

This form should be read carefully before continuing TYSABRI treatment for more than 2 years.

Treatment Discontinuation Form

This form should be read carefully before discontinuing treatment with TYSABRI.

Treatment Initiation Form

This form should be read carefully before starting treatment with TYSABRI.